메뉴 건너뛰기




Volumn 4, Issue 9, 2013, Pages 1438-1448

CXXC5 (Retinoid-Inducible Nuclear Factor, RINF) is a potential therapeutic target in high-risk human acute myeloid leukemia

Author keywords

Acute myeloid leukemia; Apoptosis; Chemotherapy; CXXC5 RINF

Indexed keywords

MESSENGER RNA;

EID: 84884684682     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1195     Document Type: Article
Times cited : (17)

References (40)
  • 9
    • 79954564425 scopus 로고    scopus 로고
    • Immunogenic apoptosis in human acute myeloid leukemia (AML): primary human AML cells expose calreticulin and release heat shock protein (HSP) 70 and HSP90 during apoptosis
    • Fredly H, Ersvaer E, Gjertsen BT, Bruserud Ø. Immunogenic apoptosis in human acute myeloid leukemia (AML): primary human AML cells expose calreticulin and release heat shock protein (HSP) 70 and HSP90 during apoptosis. Oncol Rep 2011; 25: 1549-1556.
    • (2011) Oncol Rep , vol.25 , pp. 1549-1556
    • Fredly, H.1    Ersvaer, E.2    Gjertsen, B.T.3    Bruserud, Ø.4
  • 10
    • 33750003401 scopus 로고    scopus 로고
    • Stress-induced in vitro apoptosis of native human acute myelogenous leukemia (AML) cells shows a wide variation between patients and is associated with low BCL-2:Bax ratio and low levels of heat shock protein 70 and 90
    • Ryningen A, Ersvaer E, Oyan AM, Kalland KH, Vintermyr OK, Gjertsen BT, Bruserud O. Stress-induced in vitro apoptosis of native human acute myelogenous leukemia (AML) cells shows a wide variation between patients and is associated with low BCL-2:Bax ratio and low levels of heat shock protein 70 and 90. Leuk Res 2006; 30: 1531-1540.
    • (2006) Leuk Res , vol.30 , pp. 1531-1540
    • Ryningen, A.1    Ersvaer, E.2    Oyan, A.M.3    Kalland, K.H.4    Vintermyr, O.K.5    Gjertsen, B.T.6    Bruserud, O.7
  • 11
    • 84884687111 scopus 로고    scopus 로고
    • Differences in the proliferative capacity of primary human acute myelogenous leukemia cells are associated with altered gene expression profiles and can be used for subclassification of patients
    • in press
    • Reikvam H, Øyan A, Kalland KH, Hovland R, Hatfield KJ, Bruserud Ø. Differences in the proliferative capacity of primary human acute myelogenous leukemia cells are associated with altered gene expression profiles and can be used for subclassification of patients. Cell Prolif, in press.
    • Cell Prolif
    • Reikvam, H.1    Øyan, A.2    Kalland, K.H.3    Hovland, R.4    Hatfield, K.J.5    Bruserud, Ø.6
  • 12
    • 0038712179 scopus 로고    scopus 로고
    • Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities
    • Bruserud O, Hovland R, Wergeland L, Huang TS, Gjertsen BT. Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities. Haematologica 2003; 88: 416-428.
    • (2003) Haematologica , vol.88 , pp. 416-428
    • Bruserud, O.1    Hovland, R.2    Wergeland, L.3    Huang, T.S.4    Gjertsen, B.T.5
  • 13
    • 0035176551 scopus 로고    scopus 로고
    • New strategies in the treatment of acute myelogenous leukemia (AML): in vitro culture of aml cells-the present use in experimental studies and the possible importance for future therapeutic approaches
    • Bruserud O, Gjertsen BT, Foss B, Huang TS. New strategies in the treatment of acute myelogenous leukemia (AML): in vitro culture of aml cells-the present use in experimental studies and the possible importance for future therapeutic approaches. Stem Cells 2001; 19: 1-11.
    • (2001) Stem Cells , vol.19 , pp. 1-11
    • Bruserud, O.1    Gjertsen, B.T.2    Foss, B.3    Huang, T.S.4
  • 15
    • 84873994269 scopus 로고    scopus 로고
    • Downregulation but lack of promoter hypermethylation or somatic mutations of the potential tumor suppressor CXXC5 in MDS and AML with deletion 5q
    • Treppendahl MB, Möllgård L, Hellström-Lindberg E, Cloos P, Grønbaek K. Downregulation but lack of promoter hypermethylation or somatic mutations of the potential tumor suppressor CXXC5 in MDS and AML with deletion 5q. Eur J Haematol 2013; 90: 259-260.
    • (2013) Eur J Haematol , vol.90 , pp. 259-260
    • Treppendahl, M.B.1    Möllgård, L.2    Hellström-Lindberg, E.3    Cloos, P.4    Grønbaek, K.5
  • 18
    • 84867430397 scopus 로고    scopus 로고
    • A Phase II Study of Lenalidomide Alone in Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes With Chromosome 5 Abnormalities
    • Chen Y, Kantarjian H, Estrov Z, Faderl S, Ravandi F, Rey K, Cortes J, Borthakur G. A Phase II Study of Lenalidomide Alone in Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes With Chromosome 5 Abnormalities. Clin Lymphoma Myeloma Leuk 2012; 12: 341-344.
    • (2012) Clin Lymphoma Myeloma Leuk , vol.12 , pp. 341-344
    • Chen, Y.1    Kantarjian, H.2    Estrov, Z.3    Faderl, S.4    Ravandi, F.5    Rey, K.6    Cortes, J.7    Borthakur, G.8
  • 20
    • 84875833320 scopus 로고    scopus 로고
    • Targeted anti-leukemic therapy as disease-stabilizing treatment for acute myeloid leukemia relapse after allogeneic stem cell transplantation: Will it be possible to combine these strategies with retransplantation or donor lymphocyte infusions?
    • Reikvam H, Kittang AO, Melve G, Mosevoll KA, Bentsen PT, Ersvær E, Gjertsen BT, Bruserud Ø. Targeted anti-leukemic therapy as disease-stabilizing treatment for acute myeloid leukemia relapse after allogeneic stem cell transplantation: Will it be possible to combine these strategies with retransplantation or donor lymphocyte infusions? Curr Cancer Drug Targets 2013; 13: 30-47.
    • (2013) Curr Cancer Drug Targets , vol.13 , pp. 30-47
    • Reikvam, H.1    Kittang, A.O.2    Melve, G.3    Mosevoll, K.A.4    Bentsen, P.T.5    Ersvær, E.6    Gjertsen, B.T.7    Bruserud, Ø.8
  • 24
    • 84859725212 scopus 로고    scopus 로고
    • Protection of acute myeloid leukaemia cells from apoptosis induced by front-line chemotherapeutics is mediated by haem oxygenase-1
    • Heasman SA, Zaitseva L, Bowles KM, Rushworth SA, Macewan DJ. Protection of acute myeloid leukaemia cells from apoptosis induced by front-line chemotherapeutics is mediated by haem oxygenase-1. Oncotarget 2011; 2: 658-668.
    • (2011) Oncotarget , vol.2 , pp. 658-668
    • Heasman, S.A.1    Zaitseva, L.2    Bowles, K.M.3    Rushworth, S.A.4    Macewan, D.J.5
  • 25
    • 79953665817 scopus 로고    scopus 로고
    • FLIP regulation of HO-1 and TNF signalling in human acute myeloid leukemia provides a unique secondary anti-apoptotic mechanism
    • Rushworth SA, Zaitseva L, Langa S, Bowles KM, MacEwan DJ. FLIP regulation of HO-1 and TNF signalling in human acute myeloid leukemia provides a unique secondary anti-apoptotic mechanism. Oncotarget 2010; 1: 359-366.
    • (2010) Oncotarget , vol.1 , pp. 359-366
    • Rushworth, S.A.1    Zaitseva, L.2    Langa, S.3    Bowles, K.M.4    MacEwan, D.J.5
  • 26
    • 79957462123 scopus 로고    scopus 로고
    • The heme oxygenase-1 and c-FLIP in acute myeloid leukemias: two non-redundant but mutually exclusive cellular safeguards protecting cells against TNF-induced cell death?
    • Shirley S, Micheau O. The heme oxygenase-1 and c-FLIP in acute myeloid leukemias: two non-redundant but mutually exclusive cellular safeguards protecting cells against TNF-induced cell death? Oncotarget 2010; 1: 317-319.
    • (2010) Oncotarget , vol.1 , pp. 317-319
    • Shirley, S.1    Micheau, O.2
  • 29
    • 16444374026 scopus 로고    scopus 로고
    • Constitutive activation of the Wnt/beta-catenin signalling pathway in acute myeloid leukaemia
    • Simon M, Grandage VL, Linch DC, Khwaja A. Constitutive activation of the Wnt/beta-catenin signalling pathway in acute myeloid leukaemia. Oncogene 2005; 24: 2410-2420.
    • (2005) Oncogene , vol.24 , pp. 2410-2420
    • Simon, M.1    Grandage, V.L.2    Linch, D.C.3    Khwaja, A.4
  • 32
    • 0037025173 scopus 로고    scopus 로고
    • Addiction to oncogenes - the achilles heal of cancer
    • Bernard Weinstein I. Addiction to oncogenes - the achilles heal of cancer. Science 2001; 297: 63-64.
    • (2001) Science , vol.297 , pp. 63-64
    • Bernard Weinstein, I.1
  • 34
    • 18644384085 scopus 로고    scopus 로고
    • Animal models of acute myelogenous leukaemia - development, application and future perspectives
    • McCormack E, Bruserud O, Gjertsen BT. Animal models of acute myelogenous leukaemia - development, application and future perspectives. Leukemia 2005; 19: 687-706.
    • (2005) Leukemia , vol.19 , pp. 687-706
    • McCormack, E.1    Bruserud, O.2    Gjertsen, B.T.3
  • 35
    • 45549092335 scopus 로고    scopus 로고
    • Review: genetic models of acute myeloid leukemia
    • McCormack E, Bruserud O, Gjertsen BT. Review: genetic models of acute myeloid leukemia. Oncogene 2008; 27: 3765-3779.
    • (2008) Oncogene , vol.27 , pp. 3765-3779
    • McCormack, E.1    Bruserud, O.2    Gjertsen, B.T.3
  • 36
    • 84880298933 scopus 로고    scopus 로고
    • To grab the stroma by the horns: From biology to cancer therapy with mesenchymal stem cells
    • Droujinine IA, Eckert MA, Zhao W. To grab the stroma by the horns: From biology to cancer therapy with mesenchymal stem cells. Oncotarget 2013; 4: 651-64.
    • (2013) Oncotarget , vol.4 , pp. 651-664
    • Droujinine, I.A.1    Eckert, M.A.2    Zhao, W.3
  • 37
    • 84875797043 scopus 로고    scopus 로고
    • Quantification of Mesenchymal Stem Cells (MSCs) at sites of human prostate cancer
    • Brennen WN, Chen S, Denmeade SR, Isaacs JT. Quantification of Mesenchymal Stem Cells (MSCs) at sites of human prostate cancer. Oncotarget 2013; 4: 106-17.
    • (2013) Oncotarget , vol.4 , pp. 106-117
    • Brennen, W.N.1    Chen, S.2    Denmeade, S.R.3    Isaacs, J.T.4
  • 38
    • 84862008052 scopus 로고    scopus 로고
    • Cord blood stem cells revert glioma stem cell EMT by down regulating transcriptional activation of Sox2 and Twist1
    • Velpula KK, Dasari VR, Tsung AJ, Dinh DH, Rao JS. Cord blood stem cells revert glioma stem cell EMT by down regulating transcriptional activation of Sox2 and Twist1. Oncotarget 2011; 2: 1028-42.
    • (2011) Oncotarget , vol.2 , pp. 1028-1042
    • Velpula, K.K.1    Dasari, V.R.2    Tsung, A.J.3    Dinh, D.H.4    Rao, J.S.5
  • 39
    • 84880836609 scopus 로고    scopus 로고
    • Pharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cells
    • Reikvam H, Nepstad I, Bruserud O, Hatfield KJ. Pharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cells. Oncotarget 2013; 4: 830-43.
    • (2013) Oncotarget , vol.4 , pp. 830-843
    • Reikvam, H.1    Nepstad, I.2    Bruserud, O.3    Hatfield, K.J.4
  • 40
    • 39149089296 scopus 로고    scopus 로고
    • Release of angiopoietin-1 by primary human acute myelogenous leukemia cells is associated with mutations of nucleophosmin, increased by bone marrow stromal cells and possibly antagonized by high systemic angiopoietin-2 levels
    • Hatfield KJ, Hovland R, Oyan AM, Kalland KH, Ryningen A, Gjertsen BT, Bruserud O. Release of angiopoietin-1 by primary human acute myelogenous leukemia cells is associated with mutations of nucleophosmin, increased by bone marrow stromal cells and possibly antagonized by high systemic angiopoietin-2 levels. Leukemia 2008; 22: 287-293.
    • (2008) Leukemia , vol.22 , pp. 287-293
    • Hatfield, K.J.1    Hovland, R.2    Oyan, A.M.3    Kalland, K.H.4    Ryningen, A.5    Gjertsen, B.T.6    Bruserud, O.7


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.